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Abstract
Background and Objectives: Epidemiological evidence for the role of polyunsaturated fatty-acids (PUFA) in Crohn’s disease
(CD) is unclear, although the key metabolite leucotriene B4 (LTB4) is closely linked to the inflammatory process. We
hypothesized that inherited variation in key PUFA metabolic enzymes may modify susceptibility for CD.
Methods and Principal Results: A case-control design was implemented at three pediatric gastroenterology clinics in
Canada. Children #20 yrs diagnosed with CD and controls were recruited. 19 single nucleotide polymorphisms (SNPs)
across the ALOX5 (4) CYP4F3 (5) and CYP4F2 (10) genes, were genotyped. Associations between SNPs/haplotypes and CD
were examined. A total of 431 cases and 507 controls were studied. The mean (6SD) age of the cases was 12.4 (63.3) years.
Most cases were male (56.4%), had ileo-colonic disease (L36L4, 52.7%) and inflammatory behavior (B16p, 87%) at
diagnosis. One genotyped CYP4F3 SNP (rs2683037) not in Hardy-Weinberg Equilibrium was excluded. No associations with
the remaining 4 CYP4F3 SNPs with CD were evident. However haplotype analysis revealed associations with a two-marker
haplotype (TG) (rs3794987 & rs1290617) (p=0.02; permuted p=0.08). CYP4F2 SNPs, rs3093158 (OR (recessive)=0.56, 95%
CI=0.35–0.89; p=0.01), rs2074902 (OR (trend)=1.26, 95% CI=1.00–1.60; p=0.05), and rs2108622 (OR (recessive)=1.6, 95%
CI=1.00–2.57; p=0.05) were significantly associated whereas rs1272 (OR (recessive)=0.58, 95% CI=0.30–1.13; p=0.10)
showed suggestions for associations with CD. A haplotype comprising these 4 SNPs was significantly associated (p=0.007,
permuted p=0.02) with CD. Associations with SNP rs3780901 in the ALOX5 gene were borderline non-significant (OR
(dominant)=1.29, 95% CI=0.99–1.67; p=0.056). A haplotype comprising the 4 ALOX5 SNPs (TCAA, p=0.036) was
associated with CD, but did not withstand corrections for multiple comparisons (permuted p=0.14).
Conclusions: Inherited variation in enzymes involved in the synthesis/metabolism of LTB4 may be associated with CD. These
findings implicate PUFA metabolism as a important pathway in the CD pathogenesis.
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Introduction
Crohn’s disease (CD) a chronic inflammatory bowel disease
(IBD) is common in children and appears to be on the rise in most
developing countries including Canada [1,2]. Children with CD
phenotypically differ from adults with CD and present unique
clinical challenges relative to their more aggressive disease [3–5].
Recent genome-wide association (GWA) studies both in adults
and children [6–9] have provided valuable insights on the
potential mechanisms that underlie the chronic inflammation that
is characteristic of CD. Much however remains to be known as
GWA studies have accounted for ,20% of the inherited variation
in CD [7]. CD may represent a group of heterogeneous diseases
with unique and overlapping pathophysiologies and in this
context, it remains to be explored how environmental factors
modify the expression of CD among genetically susceptible
individuals.
We have recently shown that in Canadian children an
imbalance in consumption of dietary polyunsaturated fatty acids
(PUFA) may be associated with risk for CD [10]. In particular the
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relevance, as has been proposed by others [11,12]. However,
many epidemiological studies [13] and clinical trials [14] using
sources of v fatty acids have not provided consistent results. We
hypothesized that inherited variation in the ability to metabolize
dietary PUFA may mediate development of CD and may have
contributed to the previously observed inconsistent results.
The PUFA metabolic pathway is a complex pathway involving
interplay of various enzymes [15]. Key steps relate to the release of
arachidonic acid, a v-6 fatty acid from the cell walls and synthesis
of inflammatory mediators known as eicosanoids. A key eicosanoid
is leucotriene-B4 (LTB4), a well recognized mediator of inflam-
mation. Indeed, various studies have shown that LTB4 levels are
associated with CD inflammation [16,17]. Interestingly, a recent
study has shown that the levels and activities of various enzymes
involved in the PUFA metabolic pathway that leads to production
of LTB4 were related to inflammation in IBD [18]. Three key
enzymes are the 5-LO (5-lipoxygenase) that metabolizes arachi-
donic acid and initiates the pathway and the cytochrome P450
enzymes, CYP4F3 and CYP4F2 that are known de-activators of
LTB4 [19]. In this study we investigated whether DNA variations
in these key genes were associated with CD in children.
Methods
Ethics statement
Ethical approval was acquired from the Ethics Review Board of
the Ste-Justine Hospital Foundation (HSJ), Montreal; the Chil-
dren’s Hospital of Eastern Ontario (CHEO), Ottawa; and the
British Columbia’s Children’s Hospital, Vancouver. Informed
written consent was obtained from all participants (directly from
the subject if he/she was an adult or from the parent/guardian if
otherwise).
A case-control study was carried out. Cases were children
(#20 yrs of age) diagnosed with CD and recruited from 3 pediatric
gastroenterology clinics across Canada (Montreal, Ottawa,
Vancouver). Diagnosis of CD was based on established criteria
that included clinical, radiological, endoscopic and histological
confirmation [20,21]. Disease location and behavior were
classified according to the Montreal Classification [22]. Controls
were recruited from various sources to parallel population
representativeness. These included children visiting the orthopedic
clinics for minor trauma (fractures mostly), population-based
controls (children) identified using random digit dialing, a birth
cohort and a cohort of healthy adults recruited for ongoing genetic
epidemiology studies at the Montreal study center. Cases and
controls were restricted to those with self-reported European
ancestry. Most of these controls have been previously utilized to
replicate/validate recent associations reported either in candidate
gene or GWA studies [23–28]. Blood and/or saliva were collected
as a source for DNA.
Selection of markers, genotyping & statistical analysis
Three genes, ALOX5, CYP4F3 and CYP4F2 were selected for
study as they regulate critical upstream and downstream events that
lead to production/metabolism of LTB4. Relevant markers to
genotype were identified using the tag-SNP approach [29]. The
following parameters were employed: linkage disequilibrium
(LD).0.80, minor allele frequencies .10%. Genotyping data for
populations of European origin housed at the Seattle SNPs data
resources (http://gvs.gs.washington.edu/GVS) was utilized to
select the tag-SNPs. SNPs were genotyped using the Sequenom
platform at the McGill University & Genome Quebec Innovation
Center in Montreal. Primers utilized for genotyping the SNP are
listed in table S1. Prior to analysis, Hardy-Weinberg equilibrium
(HWE) was examined in the controls. Allelic, genotype and
haplotype analysis was carried out using PLINK http://pngu.
mgh.harvard.edu/,purcell/plink) and HAPLOVIEW (http://
broad.mit.edu/mpg/HAPLOVIEW). Various models of inheri-
tance (additive, dominant, and recessive) were investigated. Odds
ratios (OR) and corresponding 95% confidence intervals (95% CI)
were estimated. P-values for the haplotype analysis were corrected
using permutation (n=10000).
Results
A total of 431 cases and 507 controls were investigated (table 1).
There were more males and the most common location of disease
was the ileo-colonic site (L36L4). Most children had inflammatory
behavior at diagnosis (B16p).
Four SNPs in the ALOX5 gene, 5 in the CYP4F3 gene and 10 in
the CYP4F2 gene were examined (table S1). SNP rs2683037 in the
CYP4F3 gene was not in HWE in the controls and was
excludedfrom further analysis. The average genotype rate was
.95%. Single SNP analysis did not reveal associations with the
CYP4F3 gene (table 2). An haplotype analysis however revealed
that the 4 markers were distributed in two blocks (table 3) of LD. A
two-marker haplotype (block 1) comprising SNPs rs394987 &
rs1290617 was significantly associated with CD (p=0.02). This
association however was borderline non-significant on permuta-
tion testing (permuted p=0.08).
For the ALOX5 gene, there were suggestions for associations
with one SNP rs3780901 (OR=1.29, 95% CI=0.99–1.67;
p=0.056) under a dominant model (table 4). Haplotype analysis
(table 5) comprising the 4 SNPs revealed 5 high frequency (.5%)
haplotypes of which haplotype TCAA was significantly associated
with CD (p=0.036). The latter associations however did not
withstand corrections for multiple comparisons (permuted
p=0.14).
Of the ten SNPs in the CYP4F2 gene investigated, three were
significantly associated with CD (table S2) under various models of
inheritance. SNP rs3093158 showed protective associations with
CD under the recessive model (OR=0.56, 95% CI=0.35–0.89;
p=0.01), SNP rs2074902 was risk conferring under the additive
model (OR=1.26, 95% CI=1.00–1.60; p=0.05), and SNP
Table 1. Clinical and demographic characteristics of the CD
patients.
Characteristic Cases (N=431)
Age at diagnosis (Mean (6SD)) 12.4 (63.3)
Gender (%) Females 188 (43.6)
Males 243 (56.4)
Disease location (%)
{ L16L4 77 (17.9)
L36L4 227 (52.7)
L26L4 123 (28.5)
Only L4 4 (0.93)
Disease behaviour (%)
{ B16p 375 (87.0)
B26p 28 (6.5)
B36p 28 (6.5)
{Disease location (L1=isolated ileal; L2=isolated colonic; L3=ileo-colonic;
L4=upper tract) and behaviour (B1=inflammatory; B2=stricturing;
B3=penetrating; p=perianal disease) was classified at diagnosis, according to
WGO’s Montreal classification.
doi:10.1371/journal.pone.0015672.t001
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95% CI=1.00–2.57; p=0.05). There were suggestions for asso-
ciations with a fourth SNP rs1272 under the recessive models
(p=0.10) but these did not achieve nominal statistical significance.
Haplotype associations (table 6) using the 4 CYP4F2 SNPs (rs1272,
rs3093158, rs2072902, and rs2108622) indicated significant asso-
ciations with haplotype GGTC (p=0.007) and marginally non-
significant associations with haplotype GACT (p=0.06). Associa-
tions with haplotype GGTC remained significant (permuted
p=0.02) after corrections for multiple comparisons.
Discussion
In this study we examined whether key enzymes within the
fatty-acid metabolic pathway were associated with risk for CD.
Although there were suggestions for associations with the ALOX5
gene at the single marker and haplotype level they did not
withstand corrections for multiple comparisons. Similarly for the
CYP4F3 gene associations were evident at the haplotype level that
were borderline non-significant on correction for multiple
comparisons. Associations were evident, both at the single marker
and haplotype level, with the CYP4F2 gene, suggesting that
variation in this gene may influence risk for CD in children.
PUFA have long been implicated in the pathogenesis of CD.
Various epidemiological investigations have been undertaken to
examine whether dietary consumption of PUFA was associated
with CD [13]. While some studies suggest that v-3 PUFA may be
beneficial and that a higher ratio of v-3/v-6 may be associated
with lower risks, evidence across studies has been inconsistent.
Similarly, potential benefits from dietary supplementation of
PUFA, have been equivocal. As individuals will differ in their
capacities to metabolize dietary PUFA, we hypothesized that DNA
variation in key genes that metabolize PUFA may be important
and may modify any associations between dietary PUFA and CD.
An important metabolite of PUFA metabolism is the generation of
LTB4 a potent mediator of inflammation. It is generated via the
metabolism of arachidonic acid, an v-6 PUFA which is the first
metabolite released from the cell membranes. It is a substrate of
the 5-LO enzyme coded by the ALOX5 gene. LTB4 derived from
the 5-LO metabolic pathway is deactivated mainly by the CYP4F3
(expressed mainly in neutrophils) and CYP4F2 (expressed largely
in the liver and kidney) enzymes. We thus selected these three
genes for study given their key roles in the metabolic pathway.
Table 2. Associations between the CYP4F3 gene and CD in
Canadian children.
SNP Model Cases Controls P-value
rs3794987 (C/T) TREND 431/453 456/514 0.46
DOM 322/120 347/138 0.66
REC 109/333 109/376 0.43
rs1290617 (G/A) TREND 314/560 373/593 0.23
DOM 255/182 301/182 0.22
REC 59/378 72/411 0.54
rs2283612 (T/G) TREND 393/487 404/562 0.22
DOM 305/135 320/163 0.32
REC 88/352 84/399 0.31
rs4646904 (C/T) TREND 160/726 173/801 0.86
DOM 145/298 162/325 0.86
REC 15/428 11/476 0.29
DOM: dominant, REC: recessive, TREND: Cochran-Armitage trend test. For this
test, the numbers in the table represent the number of chromosomes that had
the minor or the major allele.
doi:10.1371/journal.pone.0015672.t002
Table 3. Association between CYP4F3 haplotypes and CD.
Blocks Haplotype Case Control P-value
Block 1 CG 0.51 0.52 0.55
TA 0.36 0.37 0.44
TG 0.13 0.10 0.02*{
Block 2 TC 0.55 0.58 0.24
GC 0.27 0.24 0.23
GT 0.18 0.17 0.82
Block 1 (rs3794987, rs1290617); Block 2 (rs2283612, rs4646904);
*p-value,0.05;
{permuted p-value=0.08.
doi:10.1371/journal.pone.0015672.t003
Table 4. Associations between the ALOX5 gene and CD in
Canadian children.
SNP Model Cases Controls P-value
rs2115819 (C/T) TREND 394/444 437/535 0.39
DOM 296/123 334/152 0.53
REC 98/321 103/383 0.43
rs3780901 (C/T) TREND 256/592 324/652 0.17
DOM 213/211 276/212 0.056
REC 43/381 48/440 0.88
rs2291427 (A/G) TREND 249/599 314/662 0.20
DOM 209/215 264/224 0.15
REC 40/384 50/438 0.68
rs10751383 (A/C) TREND 349/495 435/541 0.17
DOM 273/149 337/151 0.16
REC 76/346 98/390 0.43
DOM: dominant, REC: recessive, TREND: Cochran-Armitage trend test. For this
test, the numbers in the table represent the number of chromosomes that had
the minor or the major allele.
doi:10.1371/journal.pone.0015672.t004
Table 5. Associations between ALOX5 haplotypes and CD.
Haplotype Cases (%) Controls (%) P-value
CTGC 0.30 0.29 0.64
TCAA 0.16 0.20 0.036*{
TTGA 0.15 0.15 0.75
TTGC 0.14 0.13 0.52
CTAC 0.06 0.05 0.39
Haplotypes comprising SNPs: rs2115819, rs3780901, rs2291427, and
rs10751383;
*p-value,0.05;
{permuted p-value=0.14.
doi:10.1371/journal.pone.0015672.t005
PUFA Metabolism and Crohn’s Disease
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e15672The CYP4F2 & CYP4F3 genes are located in a cluster on
chromosome region 19p13.2. Three genome scans have reported
significant linkages to this region in different populations. Rioux
et al (2000) [30] using affected sib-pairs reported peak LOD scores
of 4.6 for IBD and 3.0 for CD in a Canadian population. In their
recent meta-analyses of 10 IBD genome scans among affected
relatives, van Heel et al (2004) [31] reported significant linkage of
CD to chromosome 19. Low et al (2004) [32] carried out a linkage
scan among UK Caucasians (affected sib-pairs) and confirmed
linkage of CD to the 19p13.2 region (peak multi-point linkage
score of 1.59). The location of the CYP4F2 & CYP4F3 genes in the
region of significant linkage adds further support to our
observations that they may be important candidate genes for CD.
A number of previous studies have implicated LTB4 in the
pathogenesis of IBD. The greatly enhanced mucosal synthesis of
LTB4 in IBD [16,17] or in rectal diasylate [33,34] of IBD patients
has been related, in part, to the increased infiltration of neutrophils
into the intestinal tissues [35]. Of relevance to our findings are
observations that the metabolism of LTB4 by omega-hydroxylase
is altered in the colonic mucosa of IBD patients [36,37]. In
particular, the decreased activity of the omega-hydroxylases
suggested that the increased, persistent and recurrent inflamma-
tion that is characteristic of IBD may be the consequence of an
inherent defect in the metabolism of LTB4, leading to its enhanced
accumulation and activity. It is to be noted however that the
CYP4F3 enzyme is the major LTB4 omega-hydroxylase [19,38]
with higher detoxification potential as compared to CYP4F2. It
would thus have been anticipated that variations in the CYP4F3
gene were more likely to influence CD susceptibility. Our findings
however indicate that the CYP4F2 gene was more strongly
associated with CD than CYP4F3. As the tag-SNPs we selected
were of high frequency (.10%) it is possible that less frequent
SNPs in the CYP4F3 may be implicated in CD. For example SNP
rs28371536 is a non-synonymous CYP4F3 SNP of low frequency
(2%) not investigated in our study. Certainly larger studies will be
required to capture less frequent variation in the CYP4F3 gene and
to assess its influence in CD. On the other hand however, it can be
speculated that the stronger associations with the CYP4F2 gene
may be related to observations that the enzyme is not only the
major hepatic deactivator of LTB4 but is also expressed in the
small intestine [39] (although at lower levels compared to the liver)
and hence would be expected to contribute to LTB4 metabolism at
the site of inflammation as well. This dual capacity may have
contributed to the observed stronger associations. Certainly
further studies are required to clarify the roles of both CYP4F2
and CYP4F3 genes in CD pathogenesis.
Based on reported observations of elevated levels of LTB4 in
IBD and CD patients, some studies have examined the expression
of the enzymes/proteins involved in LTB4 synthesis in IBD. In one
study, Hendel et al (2002) [40] reported elevated trends in the
levels of 5-LO mRNA when studying 21 CD patients and 12
healthy controls. More recently Jupp et al (2007) [18], in a
comprehensive examination of LTB4 synthesis pathway enzymes
reported a 3-fold higher number of cells staining for 5-LO, a 7-fold
higher number of cells staining for FLAP and a 4-fold higher
number of cells staining for LTA4H in colonic biopsies of patients
with active IBD as compared to healthy controls. Although not
withstanding corrections for multiple comparisons, nominal
associations between the ALOX5 gene (that codes for the 5-LO
enzyme) were evident in our study. These observations highlight
that an abnormal prevalence of enzymes that co-ordinate to
synthesize LTB4 may be intimately linked to tissue injury and
inflammation in CD and that this pathway needs to be further
investigated.
To our knowledge no previous candidate-gene study has
examined associations between the CYP4F2 gene and CD.
Recently, Tello-Ruiz et al (2006) [41] screened variation across
the 19p IBD6 locus for associations with IBD. The SNP panel
however did not comprise variants in the CYP4F2 gene. In the
same study the authors examined 5 SNPs in the CYP4F3 gene
(including SNP rs1290617 that was part of our panel) but did not
find associations with them. Support for a potential role for the
CYP4F2 and CYP4F3 genes in IBD pathogenesis comes from
observations by Curley et al (2006) [42] who found associations
between the genes and celiac disease, a disease that bears an
inflammatory phenotype similar to CD. On the other hand
associations with CD for the three genes examined in this study
were not noted in earlier GWA studies, at the genome-wide
significance level implemented. However, in the recent GWA
study on ulcerative colitis (UC) [43], strong associations between
SNPs within the PLA2G2E (phospholipase A2, group 2E) locus
were noted in a North American Caucasian cohort. The PLA2G2E
gene codes for a secretory phospholipase A2 that releases
arachidonic acid from the cell membrane. The enzyme has been
shown to be involved in the synthesis of leucotrienes and
participate in the inflammatory process [44]. Considering that
UC and CD share pathogenetic features, the gene would be a
prime candidate gene for study in CD susceptibility and is
currently being investigated in our cohort.
It is interesting to note that of the CYP4F2 associated SNPs,
SNP rs2108622 is a non-synonymous coding SNP in exon 11
(M433V). eQTL analysis [45] indicated that the coding variation
leads to significant alteration in mRNA expression (LOD
score=3.15, p-value=0.00014). Similarly, SNP rs2074902 an
intronic SNP is in perfect LD with SNP rs3093105, a non-
synonymous coding SNP (W12G). Although eQTL data for
rs3093105 was not available, using rs2074902 as a proxy indicated
that the variation could alter mRNA expression significantly (LOD
score=2.905, p-value=0.00025). Taken together these findings
suggest that altered expression of the CYP4F2 gene may be related
to de-regulation of LTB4 metabolism that in turn can modify the
inflammatory responses.
In conclusion, our findings suggest that DNA variation in the
metabolism of LTB4 is associated with risk for CD in children.
Larger studies to replicate findings in independent cohorts and
functional studies to determine biological mechanisms are
required. Furthermore studies to investigate other potential
candidate genes in the pathway (viz. FLAP, PLA2G2E, LTA4H,
LTB4R1 etc.) need to be carried out. In addition, investigation of
interactions between dietary consumption of fatty acids and
PUFA pathway metabolic genes vis-a `-vis risk for CD need to be
pursued.
Table 6. Associations between CYP4F2 haplotypes and CD.
Haplotype Cases (%) Controls (%) P-value
GATC 0.36 0.36 0.93
CGTC 0.21 0.21 0.84
GACT 0.21 0.18 0.06
GATT 0.12 0.13 0.81
GGTC 0.09 0.13 0.007*{
Haplotypes comprising SNPs rs1272, rs3093158, rs2074902, and rs2108622;
*P-value,0.05,
{permuted p-value=0.02.
doi:10.1371/journal.pone.0015672.t006
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